medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 4

<< Back Next >>

Gac Med Mex 2017; 153 (4)

Diabetes mellitus y atrofia óptica: estudio del síndrome de Wolfram

Rivas-Gómez B, Reza-Albarrán AA

Language: Spanish
References: 61
Page: 468-474
PDF size: 157.57 Kb.


ABSTRACT

Background: Wolfram syndrome (WS), also known by the acronym DIDMOAD, is a rare and progresive hereditary disease of autosomal recessive inheritance which minimum ascertainment diagnostic criteria are the occurrence together of diabetes mellitus and optic atrophy before 15 years of age. Objective: To describe the clinical, biochemical and molecular profile of WS in a tertiary care hospital in Mexico. Materials and Methods: We reviewed patients records who fulfill the minimum ascertainment diagnostic criteria of WS presenting between January 1987 and May 2015 in a tertiary care hospital in Mexico. Results: Five patients fulfill the inclusion criteria (three male and two female). Diabetes mellitus was the first manifestation of the syndrome in all of them, with a mean age at diagnosis of 5.8 ± 2.71 years, while the WS diagnosis was established at a mean age of 15.8 ± 8.37 years. All the patients had optic atrophy and two of them presented with the complete DIDMOAD spectrum. We found new associations with autoimmune hepatitis and testicular cancer. Conclusions: This study shows the variability of clinical presentation of WS, as well as two new associations.


REFERENCES

  1. Wolfram DJ, Wagener HP. Diabetes mellitus and simple optic atrophy among siblings: report of four cases. Mayo Clin Proc. 1938;13:715-8.

  2. Rigoli L, Lombardo F, Di Bella C. Wolfram syndrome and WSF1 gene. Clin Genet. 2011;79:103-17.

  3. Kumar S. Wolfram syndrome: important implications for pediatricians and pediatric endocrinologists. Pediatric Diabetes. 2010;11:28-37.

  4. Khanim F, Kirk J, Latif F, et al. WFS1/Wolframin mutations, Wolfram syndrome, and associated diseases. Human Mutation. 2001;17:357-67.

  5. Barret TG. Mitocondrial diabetes, DIDMOAD and other inherited diabetes syndromes. Best Pract Res Clin Endocrinol Metab. 2001;15:325-43.

  6. Gómez-Zaera M, Strom TM, Rodríguez B, et al. Presence of a major WFS1 mutation in Spanish Wolfram syndrome pedigries. Mol Genet Metabol. 2001;72:72-81.

  7. Fraser FC, Gunn T. Diabetes mellitus, diabetes insipidus, and optic atrophy. An autosomal recessive syndrome? J Med Genet. 1977;14:190-3.

  8. Inoue H, Tanizawa Y, Wasson J, et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet. 1998;20:143-8.

  9. Hofmann S, Philbrook C, Gerbitz KD, et al. Wolfram syndrome: structural and functional analisys of mutante and wild-type wolframin, the WFS1 gene product. Hum Mol Genet. 2003;12:2003-12.

  10. Wang S, Kaufman RJ. The impact of the unfolded protein response on human disease. J Cell Biol. 2012;197:857-67.

  11. Fonseca SG, Gromada J, Urano F. Endoplasmic reticulum stress and pancreatic β-cell death. Trends Endocrinol Metabol. 2011;22:266-74.

  12. Zatyka M, Da Silva XG, Bellomo EA, et al. Sarco(endo)plasmic reticulum ATPase is a molecular partner of Wolfram syndrome 1 protein, wich negatively regulates its expression. Hum Mol Genet. 2015;24:814-27.

  13. Fonseca SG, Burcin M, Gromada J, et al. Endoplasmic reticulum stress in β-cells and development of diabetes. Curr Opin Pharmacol. 2009;9:763-70.

  14. Araki E, Oyadomari S, Mori M. Endoplasmic reticulum stress and diabetes mellitus. Intern Med. 2003;42:7-14.

  15. Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic β-cells and diabetes mellitus. Exp Biol Med. 2003;228:1213-7.

  16. Mozzillo E, Delvecchio M, Carella M, et al. A novel CISD2 intragenic deletion, optic neuropathy and platelet aggregation defect in Wolfram syndrome type 2. BMC Med Genet. 2014;24:15-88.

  17. Rohayem J, Ehlers C, Wiedeman B, et al. Diabetes and neurodegeneration in Wolfram syndrome. Diabetes Care. 2011;34:1503-10.

  18. Oslowski CM, Urano F. A switch from life to death in endoplasmic reticulum stressed β-cells. Diabetes Obes Metab. 2010;12 (Suppl 2):58-65.

  19. Ghirardello S, Dusi E, Castiglione B, et al. Congenital central diabetes insipidus and optic atrophy in a Wolfram newborn: is there a role for WFS1 gene in neurodevelopment? Int J Pediatr. 2014;26:40-76.

  20. Cnop M, Foufelle F, Velloso LA. Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med. 2012;18:59-68.

  21. Urano F. Wolfram syndrome iPS cells: the first human cell model of endoplasmic reticulum disease. Diabetes. 2014;63:844-6.

  22. Marshall BA, Permutt MA, Paciorkowski AR, et al. Phenotypic characteristics of early Wolfram syndrome. Orphanet J Rare Dis. 2013;27:8-64.

  23. Urano F. Targeting endoplasmic reticulum to combat juvenile diabetes. Nat Rev Endocrinol. 2014;10:129-30.

  24. Barret TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346:1458-63.

  25. Matsunaga K, Tanabe K, Inoue H, et al. Wolfram syndrome in the Japanese population; molecular analysis of WFS1 gene and characterization of clinical features. PLoS One. 2014 Sep 11;9:e106906.

  26. Ganie MA, Laway BA, Nisar S, et al. Short report: epidemiology, presentation and course of Wolfram (DIDMOAD) syndrome from North India. Diabet Med. 2011;28:1337-42.

  27. Medlej R, Wasson J, Baz P, et al. Diabetes melitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab. 2004;89:1656-61.

  28. Domènech E, Gómez-Zaera M, Nunes V. Study of the WFS1 gene and mitocondrial DNA in Spanish Wolfram syndrome families. Clin Genet. 2004;65:463-9.

  29. Chaussenot A, Rouzier C, Quere M, et al. Mutation update and uncommon phenotypes in a French cohort of 96 patients with WSF1-related disorders. Clin Genet. 2015;87:430-9.

  30. Gasparin MRR, Crispim F, Paula SL, et al. Identification of novel mutations of the WFS1 gene in Brazilian patients with Wolfram syndrome. Eur J Endocrinol. 2009;160:309-16.

  31. Aloi C, Saina A, Pasquali L, et al. Wolfram syndrome: new mutations, different phenotype. PLoS One. 2012;7:e29150.

  32. López de Heredia M, Clèries R, Nunez V. Genotypic classification of patients with Wolfram syndrome: insights into the natural history of the disease and correlation with phenotype. Genet Med. 2013;15:497-506.

  33. Barret TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet. 1997;34:838-41.

  34. Cano A, Molines L, Valero R, et al., and the French Group of Wolfram Syndrome. Microvascular diabetes complications in Wolfram syndrome (diabetes insipidus, diabetes mellitus, optic atrophy and deafness [DIDMOAD]): an age- and duration-matched comparison with common type 1 diabetes. Diabetes Care. 2007;30:2327-30.

  35. Zmyslowska A, Fendler W. Szadkowska A, et al. Glycemic variability in patients with Wolfram syndrome is lower than in type 1 diabetes. Acta Diabetol. 2015;52:1057-62.

  36. Barret TG, Bundey SE, Fielder AR, et al. Optic atrophy in Wolfram (DIDMOAD) syndrome. Eye. 1997;11:882-8.

  37. Boutzios G, Lavadas S, Marinakis E, et al. Endocrine and metabolic aspects of the Wolfram syndrome. Endocrine. 2011;40:10-3.

  38. Smith CJA, Crock PA, King BR, et al. Phenotype-genotype correlations in a series of Wolfram syndrome families. Diabetes Care. 2004;27:2003-9.

  39. Gabreels BA, Swaab DF, De Kleijn DP, et al. The vasopressin precursor is not processed in the hypothalamus of Wolfram syndrome patients with diabetes insipidus: evidence of the involvement of PC2 and 7B2. J Clin Endocrinol Metab. 1998;83:4026-33.

  40. Simsek E, Simsek T, Tekgül S, et al. Wolfram (DIDMOAD) syndrome: a multidisciplinary clinical study in nine Turkish patients and review of the literature. Acta Paediatr. 2003;92:55-61.

  41. van ven Ouweland JM, Cryns K, Pennings RJ, et al. Molecular characterization of WFS1 in patients with Wolfram syndrome. J Mol Diagn. 2003;5:88-95.

  42. Pennings RJE, Bom SJH, Cryns K, et al. Progression of low-frequency sensorineural hearing loss (DFNA6/14-WFS1). Arch Otolaryngol Head Neck Surg. 2003;129:421-6.

  43. Homa K, Stefanski A, Zmylowska A, et al. False diagnosis of type 1 diabetes mellitus and its complications in Wolfram syndrome –is it the reason for the low number of reported cases in this anormality? Endokrynologia Polska. 2014;65:5.

  44. Chaussenot A, Bannwarth S, Rouzier C, et al. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol. 2011;69:501-8.

  45. Waschbisch A, Volbers B, Struffert T, et al. Primary diagnosis of Wolfram syndrome in an adult patient – case report and description of a novel patogenic mutation. J Neurol Sci. 2011;300:191-3.

  46. Hershey T, Lugar HM, Shimony JS, et al. Early brain vulnerability in Wolfram syndrome. PLoS One. 2012;7:e40604.

  47. Mathis S, Maisonobe T, Neau JP. Neuropathy in Wolfram syndrome. Eur J Med Genet. 2011;54:73-5.

  48. Pickett KA, Duncan RP, Paciorkowski AR, et al. Balance impairment in individuals with Wolfram syndrome. Gait Posture. 2012;36:619-24.

  49. Swift M, Swift RG. Psychiatric disorders and mutations at the Wolfram syndrome locus. Biol Psychiatry. 2000;47:787-93.

  50. Sequeira A, Kim C, Seguin M, et al. Wolfram syndrome and suicide: evidence for a role of WFS1 in suicidal and impulsive behavior. Am J Med Gen B Neuropsychiatr Genet. 2003;119:108-13.

  51. Kytövuori L, Seppänen A, Martikainen MH, et al. WFS1 variants in Finnish patients with diabetes mellitus, sensorineural hearing impairment or optic atrophy, and in suicide victims. J Hum Genet. 2013;58:495-500.

  52. Sobhami M, Tabatabaifar MA, Rajab A, et al. Significant expressivity of Wolfram syndrome: phenotypic assesement of two known and one novel mutation in the WFS1 gene in three Iranian families. Mol Biol Rep. 2014;41:7499-505.

  53. Haghighi A, Haghighi A, Setoodeh A, et al. Identification of homozygous WFS1 mutations (p.Asp211Asn, p.Gln486*) causing severe Wolfram syndrome and first report of male fertility. Eur J Hum Genet. 2013;21:347-51.

  54. Lui Z, Sakakibara R, Uchiyam T, et al. Bowel dysfunction in Wolfram syndrome. Diabetes Care. 2006;29:472-3.

  55. Hardy C, Khanim F, Torres R, et al. Clinical and molecular genetic analysis of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in WFS1. Am J Hum Genet. 1999;65:1279-90.

  56. D’Annunzio G, Minuto N, D’Amato E, et al. Wolfram syndrome (diabetes insipidus, diabetes, optic atrophy, and deafness). Clinical and genetic study. Diabetes Care. 2008;31:1743-45.

  57. Cryns K, Sivakumaran TA, Van den Ouweland JM, et al. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus and psychiatric disease. Human Mutation. 2003;22:275-87.

  58. Yu G, Yu M, Wang J, et al. WS1 gene mutation analysis of Wolfram syndrome in a Chinese patient and a systematic review of literature. Endocrine. 2010;38:147-52.

  59. Sobhani M, Tabatabaiefar MA, Rajab A, et al. Molecular characterization of WFS1 in an Iranian family with Wolfram syndrome reveals a novel frameshift mutation associated with early symptoms. Gene. 2013;528:309-13.

  60. Zenteno JC, Ruiz G, Pérez-Cano HJ, et al. Familial Wolfram syndrome due to compound heterozygosity for two novel WFS1 mutations. Mol Vis. 2008;14:1353-7.

  61. Blanco-Aguirre ME, la Parra DR, Tapia-Garcia H, et al. Identification of unsuspected Wolfram syndrome cases through clinical assessment and WFS1 gene screening in type 1 diabetes mellitus patients. Gene. 2015;15:63-7.




2020     |     www.medigraphic.com